patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_977042 | REC_0017901 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.5 | 61 | male | 1 | 18 | 6.4 | 3 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:36:02.801514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496622 | REC_0017902 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 13.6 | 69 | female | 0 | 17 | 5.3 | 5 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:36:02.802525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280561 | REC_0017903 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 15.3 | 71 | female | 1 | 12 | 4.2 | 0 | osimertinib 80 mg daily | 27.4 | false | MSI-H | 2026-03-15T05:36:02.803239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197851 | REC_0017904 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10 | 75 | female | 2 | 24 | 6.1 | 7 | entrectinib 600 mg daily | 9 | false | MSS | 2026-03-15T05:36:02.803937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251119 | REC_0017905 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.1 | 66 | female | 0 | 0 | 6.2 | 1 | osimertinib 80 mg daily | 22.7 | true | MSS | 2026-03-15T05:36:02.804773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414463 | REC_0017906 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 16.6 | 68 | female | 1 | 14 | 4.3 | 1 | alectinib 600 mg BID | 9.4 | false | MSI-H | 2026-03-15T05:36:02.805524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699151 | REC_0017907 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 8.3 | 79 | female | 2 | 18 | 3.4 | 4 | entrectinib 600 mg daily | 12.7 | false | MSS | 2026-03-15T05:36:02.806276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815257 | REC_0017908 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 16.2 | 65 | female | 0 | 15 | 6.5 | 6 | osimertinib 80 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:36:02.807010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379105 | REC_0017909 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7.3 | 68 | male | 1 | 74 | 6.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:36:02.807752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222689 | REC_0017910 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.8 | 52 | male | 0 | 19 | 6.2 | 2 | osimertinib 80 mg daily | 25 | true | MSS | 2026-03-15T05:36:02.808611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762992 | REC_0017911 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.7 | 63 | female | 0 | 38 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.5 | true | MSS | 2026-03-15T05:36:02.809471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111241 | REC_0017912 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.5 | 62 | female | 0 | 7 | 6.2 | 4 | alectinib 600 mg BID | 16.2 | true | MSS | 2026-03-15T05:36:02.810243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700149 | REC_0017913 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14 | 60 | male | 0 | 11 | 4.6 | 4 | alectinib 600 mg BID | 17.4 | false | MSI-H | 2026-03-15T05:36:02.811040+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463113 | REC_0017914 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9 | 61 | male | 1 | 20 | 4.4 | 4 | alectinib 600 mg BID | 14.3 | true | MSS | 2026-03-15T05:36:02.811845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_642126 | REC_0017915 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 23 | 6.2 | 64 | female | 0 | 31 | 4.8 | 0 | pembrolizumab 200 mg q3w | 41.9 | true | MSS | 2026-03-15T05:36:02.813064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964648 | REC_0017916 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 4.4 | 71 | male | 1 | 17 | 4.2 | 2 | osimertinib 80 mg daily | 22.4 | true | MSS | 2026-03-15T05:36:02.813954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110829 | REC_0017917 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 16.9 | 75 | female | 2 | 17 | 8.2 | 6 | osimertinib 80 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:36:02.814773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102322 | REC_0017918 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 7.4 | 43 | male | 0 | 37 | 4 | 1 | pembrolizumab 200 mg q3w | 7 | false | MSS | 2026-03-15T05:36:02.815625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730438 | REC_0017919 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 8.6 | 65 | female | 1 | 12 | 5.6 | 2 | alectinib 600 mg BID | 21.5 | false | MSS | 2026-03-15T05:36:02.816494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679900 | REC_0017920 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13.2 | 74 | female | 2 | 14 | 5.6 | 6 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:36:02.817358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899986 | REC_0017921 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 28 | 11 | 61 | female | 1 | 14 | 9 | 0 | osimertinib 80 mg daily | 44.9 | false | MSS | 2026-03-15T05:36:02.818215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123048 | REC_0017922 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 16.1 | 67 | female | 1 | 13 | 9.1 | 5 | alectinib 600 mg BID | 10.9 | true | MSS | 2026-03-15T05:36:02.819073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144942 | REC_0017923 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.6 | 57 | male | 1 | 21 | 3.5 | 7 | osimertinib 80 mg daily | 15 | false | MSI-H | 2026-03-15T05:36:02.819876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216254 | REC_0017924 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.9 | 66 | female | 0 | 23 | 6.3 | 6 | alectinib 600 mg BID | 5.7 | true | MSI-H | 2026-03-15T05:36:02.820788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629027 | REC_0017925 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.8 | 81 | female | 2 | 17 | 7.4 | 6 | alectinib 600 mg BID | 9.6 | false | MSS | 2026-03-15T05:36:02.821604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220326 | REC_0017926 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 19 | 6.9 | 75 | female | 2 | 48 | 5.3 | 1 | pembrolizumab 200 mg q3w | 17.2 | false | MSS | 2026-03-15T05:36:02.822387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599613 | REC_0017927 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7 | 72 | female | 2 | 53 | 6.5 | 6 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:36:02.823218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433207 | REC_0017928 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 29 | 6.1 | 66 | female | 1 | 15 | 6.5 | 0 | entrectinib 600 mg daily | 31.8 | false | MSS | 2026-03-15T05:36:02.824389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867692 | REC_0017929 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 7.6 | 58 | male | 0 | 58 | 5.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:36:02.825293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602398 | REC_0017930 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 10.9 | 75 | female | 1 | 18 | 5.8 | 2 | pembrolizumab 200 mg q3w | 18.2 | true | MSS | 2026-03-15T05:36:02.826104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448352 | REC_0017931 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.2 | 82 | female | 1 | 12 | 5 | 4 | osimertinib 80 mg daily | 7.7 | false | MSS | 2026-03-15T05:36:02.826843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155748 | REC_0017932 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 5.7 | 65 | male | 1 | 66 | 7.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:36:02.827606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413647 | REC_0017933 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 6.5 | 66 | female | 1 | 5 | 6.9 | 5 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:36:02.828487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556385 | REC_0017934 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 17.8 | 59 | female | 1 | 10 | 3.9 | 1 | osimertinib 80 mg daily | 20.9 | false | MSS | 2026-03-15T05:36:02.829322+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727551 | REC_0017935 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 9.2 | 60 | male | 0 | 14 | 5.9 | 2 | osimertinib 80 mg daily | 21.8 | true | MSS | 2026-03-15T05:36:02.830153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762110 | REC_0017936 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 9 | 70 | male | 1 | 11 | 6.3 | 2 | alectinib 600 mg BID | 8.4 | false | MSS | 2026-03-15T05:36:02.830911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759584 | REC_0017937 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 11.5 | 62 | male | 1 | 15 | 6.1 | 5 | osimertinib 80 mg daily | 12.9 | false | MSI-H | 2026-03-15T05:36:02.831840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_213381 | REC_0017938 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 6.9 | 70 | female | 1 | 40 | 7.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | true | MSS | 2026-03-15T05:36:02.832773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457608 | REC_0017939 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 19.4 | 63 | male | 0 | 17 | 6.2 | 7 | entrectinib 600 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:36:02.833623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_365354 | REC_0017940 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.6 | 78 | female | 2 | 11 | 5.8 | 4 | sotorasib 960 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:36:02.834377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752400 | REC_0017941 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 10.3 | 65 | male | 1 | 11 | 6 | 1 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:36:02.835440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490995 | REC_0017942 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 29 | 10.3 | 82 | male | 1 | 20 | 4.4 | 0 | alectinib 600 mg BID | 11.8 | true | MSI-H | 2026-03-15T05:36:02.836316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870212 | REC_0017943 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 20.1 | 67 | male | 1 | 15 | 5.1 | 1 | sotorasib 960 mg daily | 19.9 | false | MSI-H | 2026-03-15T05:36:02.837131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960615 | REC_0017944 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 8.9 | 68 | male | 0 | 21 | 7.2 | 4 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:36:02.837889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973921 | REC_0017945 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 26 | 7.1 | 69 | male | 0 | 23 | 2.9 | 2 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:36:02.838600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174294 | REC_0017946 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 14.8 | 54 | female | 0 | 21 | 5 | 2 | alectinib 600 mg BID | 25.6 | true | MSI-H | 2026-03-15T05:36:02.839360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568217 | REC_0017947 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 9.1 | 61 | male | 1 | 11 | 6.6 | 1 | entrectinib 600 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:02.840180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871413 | REC_0017948 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13.1 | 78 | female | 2 | 12 | 6.5 | 5 | osimertinib 80 mg daily | 15.1 | true | MSS | 2026-03-15T05:36:02.840927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596332 | REC_0017949 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 7.7 | 69 | female | 1 | 32 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.8 | false | MSS | 2026-03-15T05:36:02.841621+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810832 | REC_0017950 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 16.1 | 64 | male | 0 | 20 | 5.4 | 0 | sotorasib 960 mg daily | 20.6 | false | MSS | 2026-03-15T05:36:02.842414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343963 | REC_0017951 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 13.2 | 62 | male | 0 | 13 | 6 | 4 | alectinib 600 mg BID | 9 | false | MSS | 2026-03-15T05:36:02.843136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943678 | REC_0017952 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 6.1 | 67 | female | 1 | 50 | 7.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 4.6 | true | MSS | 2026-03-15T05:36:02.843821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151547 | REC_0017953 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.9 | 55 | female | 1 | 22 | 4.4 | 7 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:36:02.844678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961761 | REC_0017954 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.1 | 67 | female | 0 | 18 | 6 | 5 | entrectinib 600 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:36:02.845663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407745 | REC_0017955 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12 | 74 | female | 2 | 9 | 7.1 | 6 | alectinib 600 mg BID | 10.9 | true | MSS | 2026-03-15T05:36:02.846358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938613 | REC_0017956 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.5 | 51 | female | 0 | 4 | 5.5 | 9 | alectinib 600 mg BID | 12.2 | true | MSI-H | 2026-03-15T05:36:02.847049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176184 | REC_0017957 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 15.6 | 71 | female | 1 | 11 | 6 | 1 | osimertinib 80 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:36:02.847773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231360 | REC_0017958 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 7.3 | 51 | female | 0 | 26 | 5.9 | 6 | entrectinib 600 mg daily | 15.8 | true | MSS | 2026-03-15T05:36:02.848627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855902 | REC_0017959 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 14.6 | 67 | female | 0 | 8 | 6.7 | 4 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:36:02.849479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844810 | REC_0017960 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 17 | 20 | 51 | female | 0 | 18 | 5.1 | 0 | entrectinib 600 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:36:02.850303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_325827 | REC_0017961 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 12.6 | 58 | male | 0 | 16 | 6.6 | 6 | osimertinib 80 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:36:02.851070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831547 | REC_0017962 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.7 | 60 | male | 1 | 19 | 4.7 | 1 | pembrolizumab 200 mg q3w | 13.7 | true | MSS | 2026-03-15T05:36:02.851824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803101 | REC_0017963 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 6.5 | 70 | female | 1 | 15 | 7.7 | 6 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:02.852685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184317 | REC_0017964 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 15.2 | 56 | male | 1 | 9 | 5.3 | 10 | osimertinib 80 mg daily | 10.7 | false | MSS | 2026-03-15T05:36:02.853520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106876 | REC_0017965 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.9 | 75 | male | 1 | 12 | 7.2 | 2 | pembrolizumab 200 mg q3w | 21.6 | false | MSS | 2026-03-15T05:36:02.854287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_699191 | REC_0017966 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 12.7 | 62 | male | 1 | 20 | 5.9 | 6 | entrectinib 600 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:02.855048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570951 | REC_0017967 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 11.7 | 52 | female | 0 | 19 | 5.1 | 2 | osimertinib 80 mg daily | 23.1 | true | MSS | 2026-03-15T05:36:02.856016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702217 | REC_0017968 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.8 | 57 | male | 1 | 57 | 3.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:36:02.856956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996539 | REC_0017969 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 24 | 7.1 | 74 | female | 1 | 0 | 5.8 | 0 | pembrolizumab 200 mg q3w | 37.6 | true | MSS | 2026-03-15T05:36:02.857709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912905 | REC_0017970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 4.8 | 76 | female | 2 | 16 | 5.1 | 1 | osimertinib 80 mg daily | 21.6 | true | MSS | 2026-03-15T05:36:02.858439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149471 | REC_0017971 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 6.5 | 62 | female | 0 | 10 | 4.9 | 1 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:36:02.859218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870041 | REC_0017972 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.2 | 78 | female | 1 | 21 | 6.7 | 8 | entrectinib 600 mg daily | 10.4 | false | MSI-H | 2026-03-15T05:36:02.859954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257918 | REC_0017973 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 9.8 | 77 | female | 1 | 18 | 3.6 | 4 | entrectinib 600 mg daily | 7.2 | true | MSS | 2026-03-15T05:36:02.860772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317867 | REC_0017974 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 4.2 | 60 | male | 0 | 19 | 5.8 | 6 | pembrolizumab 200 mg q3w | 9.9 | false | MSS | 2026-03-15T05:36:02.861516+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485829 | REC_0017975 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 8.2 | 70 | female | 2 | 10 | 3.6 | 2 | osimertinib 80 mg daily | 27.5 | false | MSS | 2026-03-15T05:36:02.862298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998224 | REC_0017976 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.7 | 74 | female | 1 | 10 | 7 | 8 | osimertinib 80 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:36:02.863051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410145 | REC_0017977 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 20 | 3.7 | 77 | female | 1 | 9 | 4.8 | 7 | pembrolizumab 200 mg q3w | 11.5 | true | MSS | 2026-03-15T05:36:02.863810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178795 | REC_0017978 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 10.1 | 63 | female | 0 | 20 | 7.8 | 1 | osimertinib 80 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:36:02.864682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612323 | REC_0017979 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 8.7 | 68 | female | 0 | 38 | 9.2 | 1 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:36:02.865465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964365 | REC_0017980 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 8.9 | 71 | male | 2 | 12 | 4.2 | 5 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:36:02.866508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633808 | REC_0017981 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5 | 63 | male | 0 | 49 | 3.9 | 1 | pembrolizumab 200 mg q3w | 5.6 | false | MSS | 2026-03-15T05:36:02.867290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158846 | REC_0017982 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 15.2 | 61 | female | 0 | 6 | 3.8 | 5 | entrectinib 600 mg daily | 4.9 | true | MSS | 2026-03-15T05:36:02.868132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796133 | REC_0017983 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 10.5 | 53 | female | 0 | 20 | 7 | 1 | alectinib 600 mg BID | 15.3 | true | MSS | 2026-03-15T05:36:02.868912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210153 | REC_0017984 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.9 | 58 | female | 1 | 25 | 6.4 | 4 | osimertinib 80 mg daily | 4.9 | true | MSI-H | 2026-03-15T05:36:02.869711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982997 | REC_0017985 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 9.4 | 63 | female | 1 | 12 | 4.9 | 3 | alectinib 600 mg BID | 13.2 | false | MSS | 2026-03-15T05:36:02.870454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349509 | REC_0017986 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 8.2 | 80 | female | 1 | 8 | 4.3 | 6 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:02.871217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961976 | REC_0017987 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 11 | 11.7 | 78 | female | 1 | 22 | 5.1 | 8 | pembrolizumab 200 mg q3w | 6.8 | true | MSS | 2026-03-15T05:36:02.871975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_759067 | REC_0017988 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 3.9 | 74 | female | 2 | 16 | 4.8 | 7 | pembrolizumab 200 mg q3w | 15.9 | true | MSS | 2026-03-15T05:36:02.872865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467931 | REC_0017989 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8 | 64 | male | 0 | 12 | 5.5 | 4 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:36:02.873616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294036 | REC_0017990 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 3.8 | 61 | male | 1 | 20 | 4.2 | 1 | osimertinib 80 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:02.874337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188580 | REC_0017991 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 10.8 | 64 | female | 0 | 9 | 4.2 | 2 | alectinib 600 mg BID | 21.1 | true | MSS | 2026-03-15T05:36:02.875102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184551 | REC_0017992 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 9.7 | 69 | male | 1 | 15 | 7.1 | 2 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:02.875861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615049 | REC_0017993 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 8.6 | 61 | male | 1 | 17 | 7.2 | 2 | pembrolizumab 200 mg q3w | 17.5 | false | MSS | 2026-03-15T05:36:02.876954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416827 | REC_0017994 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.2 | 68 | female | 0 | 73 | 6.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:02.877763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786419 | REC_0017995 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.8 | 64 | male | 1 | 20 | 6.7 | 2 | alectinib 600 mg BID | 14.2 | true | MSS | 2026-03-15T05:36:02.878478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300028 | REC_0017996 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9.3 | 72 | female | 1 | 29 | 6.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:36:02.879230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543188 | REC_0017997 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 15.7 | 74 | female | 2 | 22 | 5.7 | 1 | entrectinib 600 mg daily | 18.5 | false | MSS | 2026-03-15T05:36:02.880021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440803 | REC_0017998 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 18.8 | 66 | female | 1 | 14 | 6 | 3 | alectinib 600 mg BID | 14.1 | true | MSI-H | 2026-03-15T05:36:02.881000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835549 | REC_0017999 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.8 | 63 | female | 0 | 9 | 5.5 | 4 | sotorasib 960 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:36:02.881726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276823 | REC_0018000 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.1 | 61 | male | 1 | 23 | 5.7 | 9 | entrectinib 600 mg daily | 13.8 | false | MSI-H | 2026-03-15T05:36:02.882523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.